HC Wainwright Has Bullish Forecast for ACXP FY2024 Earnings

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Equities researchers at HC Wainwright increased their FY2024 EPS estimates for Acurx Pharmaceuticals in a research note issued on Thursday, November 14th. HC Wainwright analyst E. Arce now anticipates that the company will earn ($0.89) per share for the year, up from their previous forecast of ($0.98). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q4 2024 earnings at ($0.18) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.06) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($3.18) EPS and FY2028 earnings at ($3.35) EPS.

Acurx Pharmaceuticals Trading Down 1.8 %

Shares of ACXP opened at $1.67 on Monday. The stock has a 50 day moving average of $1.94 and a 200 day moving average of $2.13. Acurx Pharmaceuticals has a 12 month low of $1.52 and a 12 month high of $5.28. The company has a market capitalization of $28.21 million, a price-to-earnings ratio of -1.53 and a beta of -1.73.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. During the same quarter in the prior year, the firm posted ($0.24) EPS.

Institutional Investors Weigh In On Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC boosted its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 1.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 278,100 shares of the company’s stock after acquiring an additional 5,250 shares during the period. Prospect Financial Services LLC owned 1.76% of Acurx Pharmaceuticals worth $626,000 as of its most recent filing with the SEC. 11.53% of the stock is currently owned by institutional investors.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.